Revenue Breakdown
Composition ()
No data
Revenue Streams
Aclaris Therapeutics Inc (ACRS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Licensing, accounting for 85.3% of total sales, equivalent to $2.81M. Another important revenue stream is Laboratory Research Revenue. Understanding this composition is critical for investors evaluating how ACRS navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Aclaris Therapeutics Inc maintains a gross margin of 25.77%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -516.79%, while the net margin is -442.98%. These profitability ratios, combined with a Return on Equity (ROE) of -113.23%, provide a clear picture of how effectively ACRS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ACRS competes directly with industry leaders such as SIGA and VNDA. With a market capitalization of $390.04M, it holds a significant position in the sector. When comparing efficiency, ACRS's gross margin of 25.77% stands against SIGA's 61.75% and VNDA's 91.63%. Such benchmarking helps identify whether Aclaris Therapeutics Inc is trading at a premium or discount relative to its financial performance.
